



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2011

A sensitized RNA interference screen identifies a novel role for the PI3K p110 isoform in medulloblastoma cell proliferation and chemoresistance

Guerreiro, A S ; Fattet, S ; Kulesza, D W ; Atamer, A ; Elsing, A N ; Shalaby, T ; Jackson, S P ; Schoenwaelder, S M ; Grotzer, M A ; Delattre, O ; Arcaro, A

Abstract: Medulloblastoma is the most common malignant brain tumor in children and is associated with a poor outcome. We were interested in gaining further insight into the potential of targeting the human kinome as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small interfering RNA (siRNA) was used to downregulate the known human protein and lipid kinases in medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising ATR, LYK5, MPP2, PIK3CG, PIK4CA, and WNK4 were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed overexpression of LYK5 and PIK3CG. The results of the siRNA screen were validated by target inhibition with specific pharmacological inhibitors. A pharmacological inhibitor of p110 (encoded by PIK3CG) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our data show that the p110 phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma.

DOI: <https://doi.org/10.1158/1541-7786.MCR-10-0200>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-55459>

Journal Article

Accepted Version

Originally published at:

Guerreiro, A S; Fattet, S; Kulesza, D W; Atamer, A; Elsing, A N; Shalaby, T; Jackson, S P; Schoenwaelder, S M; Grotzer, M A; Delattre, O; Arcaro, A (2011). A sensitized RNA interference screen identifies a novel role for the PI3K p110 isoform in medulloblastoma cell proliferation and chemoresistance. *Molecular Cancer Research*, 9(7):925-935.

DOI: <https://doi.org/10.1158/1541-7786.MCR-10-0200>

Molecular Cancer Research



A sensitized RNA interference screen identifies a novel role for the PI3K p110 γ isoform in medulloblastoma cell proliferation and chemoresistance

Ana S Guerreiro, Sarah Fattet, Dorota Kulesza, et al.

Mol Cancer Res Published OnlineFirst June 7, 2011.

Updated version	Access the most recent version of this article at: doi: 10.1158/1541-7786.MCR-10-0200
Supplementary Material	Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2011/06/02/1541-7786.MCR-10-0200.DC1.html
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .

A sensitized RNA interference screen identifies a novel role for the PI3K p110 γ isoform in medulloblastoma cell proliferation and chemoresistance

Ana S. Guerreiro ¹, Sarah Fattet ^{2,3}, Dorota W. Kulesza ¹, Abdullah Atamer ¹, Alexandra N. Elsing ¹, Tarek Shalaby ¹, Shaun P. Jackson ⁴, Simone M. Schoenwaelder ⁴, Michael A. Grotzer ¹, Olivier Delattre ², and Alexandre Arcaro ^{1,5}

¹ Department of Oncology, University Children's Hospital, Zurich, Switzerland

² Laboratoire de Pathologie Moléculaire des Cancers, Institut Curie, Paris, France

³ Unité d'Hématologie et Oncologie Pédiatrique, Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland

⁴ Australian Centre for Blood Diseases, Monash University, 6th Floor Burnet Building Alfred Medical Research and Education Precinct, Prahran, Victoria, Australia

⁵ Division of Pediatric Hematology/Oncology, Department of Clinical Research, University of Bern, Switzerland

Requests for reprints: Alexandre Arcaro, University of Bern, Department of Clinical Research, Tiefenaustasse 120c, 3004 Bern, Switzerland. Tel. +41 31 308 80 29; FAX +41 31 308 80 28; Email alexandre.arcaro@dkf.unibe.ch

Grant Support: This work was supported by grants from the Werner und Hedy Berger-Janser – Stiftung zur Erforschung der Krebskrankheiten, the Forschungskredit der Universität Zürich, the Fondation FORCE, the Stiftung zur Krebsbekämpfung and the European Community FP7 (ASSET, project number: 259348) to AA.

Running title: Role of p110 γ in medulloblastoma

Keywords: medulloblastoma; phosphoinositide 3-kinase; Akt; apoptosis; chemoresistance

Abstract

Medulloblastoma is the most common malignant brain tumour in children and is associated with a poor outcome. We were interested in gaining further insight into the potential of targeting the human kinome as a novel approach to sensitize medulloblastoma to chemotherapeutic agents. A library of small interfering RNA (siRNA) was used to down-regulate the known human protein and lipid kinases in medulloblastoma cell lines. The analysis of cell proliferation, in the presence or absence of a low dose of cisplatin after siRNA transfection, identified new protein and lipid kinases involved in medulloblastoma chemoresistance. PLK1 (polo-like kinase 1) was identified as a kinase involved in proliferation in medulloblastoma cell lines. Moreover, a set of 6 genes comprising *ATR*, *LYK5*, *MPP2*, *PIK3CG*, *PIK4CA* and *WNK4* were identified as contributing to both cell proliferation and resistance to cisplatin treatment in medulloblastoma cells. An analysis of the expression of the 6 target genes in primary medulloblastoma tumor samples and cell lines revealed over-expression of *LYK5* and *PIK3CG*. The results of the siRNA screen were validated by target inhibition with specific pharmacological inhibitors. A pharmacological inhibitor of p110 γ (encoded by *PIK3CG*) impaired cell proliferation in medulloblastoma cell lines and sensitized the cells to cisplatin treatment. Together, our data show that the p110 γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma.

Introduction

Medulloblastoma is the most common malignant brain tumour in children and accounts for approximately 20% to 25% of all pediatric central nervous system tumours (1). There are hundreds of new cases worldwide each year, most of which occur at between 5 and 10 years of age (1, 2). Treatment of medulloblastoma involves surgery followed by chemotherapy and, in the case of children older than 3-5 years, radiotherapy (3, 4). Although these therapeutic approaches are often effective at shrinking the primary tumour, recurrence and metastasis frequently occur, so that the 5-year survival rate is below 50% for high-risk patients. Novel therapies are thus urgently required and will arise from a better understanding of the disease biology.

Several reports have documented the involvement of protein and lipid kinases in medulloblastoma biology. Receptor tyrosine kinases (RTKs) such as ErbB-2, ErbB-4, insulin-like growth factor-I receptor (IGF-IR) and platelet-derived growth factor receptor (PDGFR) have been shown to be expressed and to control cell proliferation, survival and the development of metastasis in human medulloblastoma cells (1, 5). New therapies for medulloblastoma are emerging, which are based on blocking signalling by these RTKs to some of their downstream signalling targets such as phosphoinositide 3-kinase (PI3K), protein kinase B (PKB)/Akt, the mammalian target of rapamycin (mTOR) and mitogen-activated extracellular signal-regulated kinase activating kinase (MEK) (6-12).

The ability to use RNA interference (RNAi) as a tool for gene silencing in mammalian cells has opened up the possibility of carrying out high-throughput loss-of-function screens in tissue culture systems (13-16). To identify new molecular targets for medulloblastoma, we have performed survival RNA interference (RNAi) screens targeting most of the known human protein and lipid kinases (719 genes) using libraries of either short hairpin RNA (shRNA) in retroviral constructs, or small interfering RNA (siRNA). The analysis of cell proliferation after RNAi transfection in combination with cisplatin treatment identified new protein and lipid kinases involved in medulloblastoma cell responses. In particular, p110 γ and LYK5, two kinases which had not previously been implicated in medulloblastoma biology, were shown to play a role in cell proliferation and chemoresistance by contributing to activation of the mTOR pathway.

Materials and methods

siRNA library and screen set up

DAOY medulloblastoma cells were transfected with a 96 well plate arrayed siRNA kinome library (Ambion) containing 2157 unique small interfering RNAs (siRNAs) targeting each of the 719 human kinase genes (3 individual siRNAs per gene). DAOY cells (4500 cells in 100 μ l medium/well) were plated in DMEM (Dulbecco's modified Eagle's medium; Invitrogen) containing 10% FCS and 1% L-glutamine and allowed to attach. siRNA transfections (5 pmol siRNA/well) were performed using Lipofectamine 2000 (Invitrogen) as per manufacture's instructions for adherent cell lines, in two identical replica plates. At 24h after transfection, one replica plate was treated with 0.5 μ M cisplatin (Bristol-Myers Squibb) and one replica plate with vehicle in media. Cell viability was assessed after further 48h by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega). On each plate, siRNA for GAPDH (Ambion), siCONTROL Non-Targeting siRNA Pool (Dharmacon) and siCONTROL RISC-Free siRNA (Dharmacon) were used as negative controls (one well each) and siCONTROL TOX was used as positive control for transfection efficiency. The screen was performed in triplicate and, for each individual siRNA, the mean values of the three independent experiments were calculated. The effect of each siRNA on cell proliferation was assessed dividing the mean of the 3 replica wells by the mean of the 3 negative controls of the corresponding plate, and expressed as a percentage. For determination of the sensitivity to cisplatin treatment, surviving fractions were calculated as follows: Surviving fraction = \log_2 mean (three replica cisplatin-treated wells) - \log_2 mean (three replica vehicle-treated wells). In order to allow comparisons, the surviving fraction from all 27 RNAi plates were combined and expressed as a median-centred Z score. Z-score normalization of the data within each well location of the plate was performed, subtracting the median surviving fraction from the surviving fraction of the individual siRNA and then dividing the difference by the standard deviation. The correction factor 1.4826 for large population size was used. To define effects on cisplatin resistance, a threshold of $Z \leq -2$ for sensitization was used.

Screen validation, shRNAs and plasmid transfections

Two distinct siRNA species and one shRNA were used to revalidate hits from the screen. The siRNA sequences used for validation were the same as the ones used in the screen. Ambion Catalog

numbers of the siRNA sequences were used: PIK3CG#1 – ID: 143808, PIK3CG#2 – ID: 143807, PLK#1 – ID: 103548, PLK#2 – ID: 1341, LYK5#1 – ID: 43040, LYK5#2 – ID: 43116, ATR#1 – ID: 103302, ATR#2 – ID: 82, PI4KA#1 – ID: 1604, PI4KA#2 – ID: 144408, WNK4#1 – ID: 1105, WNK4#2 – ID: 1106. RNAi-mediated gene silencing was evaluated 48h after transfection. mRNA and protein were extracted in order to assess protein expression by Western blotting and mRNA expression by quantitative PCR. The shRNA-encoding plasmids used are part of the Human Kinase shRNA Release 1.A2 library (Open Biosystems). The following plasmids were used: v2HS_36776 (MPP2), v2HS_179927 (LYK5) and v2HS_170020 (PIK3CG). The negative control vector (pSM2) containing a non-targeting shRNA sequence was used as shRNA control. To transfect DAOY medulloblastoma cells with plasmids, the Lipofectamine Plus reagent (Invitrogen) was used according to the manufacturer's recommended protocol.

Clinical samples

Ethical approval to use residual tissue was obtained for all primary medulloblastoma samples used in this study. The samples used in this study and methods for RNA extraction have been previously described (17). Forty-seven medulloblastoma samples collected at diagnosis in a single institution between 1992 and 2004 (Dr. Lellouch-Tubiana, Necker Hospital, Paris) according to the French law of bioethics (Loi Huriet) were used for gene expression analyses. An independent set of 10 RNA-later-preserved tumor tissues from the Swiss Pediatric Oncology Group Tumor Bank was obtained for mRNA and protein expression analysis.

Expression profiling

Gene expression profiles were obtained on the Affymetrix HG-U133 Plus 2.0 array, containing over 54000 probe sets for transcripts and variants (17). The GCRMA procedure was used for normalization of gene expression data, which were subsequently converted into log₂-values. Probes of interest have been considered for analysis and compared to expression levels of 9 normal cerebellum samples (GSM80616, GSM80617, GSM80618, GSM80619, GSM80626, GSM80636, GSM80637, GSM80638, and GSM80639; expression data are available on the public database Gene Expression Omnibus: <http://www.ncbi.nlm.nih.gov/geo/>).

TaqMan real time quantitative RT-PCR

Total RNA from each tumour sample was converted into cDNA using the SuperScript™ First-Strand Synthesis System (Invitrogen) for PCR according to manufacturer's instructions. Assays-on-Demand Gene Expression products (Applied Biosystems) were used to measure mRNA expression levels of PLK1 (Hs00153444_m1), LYK5 (Hs00405851_m1), MPP2 (Hs00178428_m1), PIK3CG (Hs00176916_m1), PI4KA (Hs01021084_m1), WNK4 (Hs00260769_m1), ATR (Hs00354807_m1) and GAPDH (Hs99999905_m1; internal control gene). Normal human cerebellum was used as a reference (BioCat GmbH). Relative mRNA expression levels were calculated using the comparative threshold cycle (CT) method (18).

Cell culture and treatments

The cell lines' provenience has been previously described (19). DAOY, UW-228 and PFSK human cell lines were purchased from the American Type Culture Collection. D341 and D425 MB cells were the kind gift of Dr. Henry Friedman (Duke University, Durham, NC). Cell lines that were not purchased from the American Type Culture Collection in 2009 were tested for their authentication by karyotypic analysis using molecular cytogenetic techniques, such as comparative genomic hybridization. DAOY medulloblastoma cell line was grown in Richter's MEM Zinc option medium (Invitrogen) with 10% FCS (fetal bovine serum; Sigma) and penicillin/streptomycin (Invitrogen). PFSK primitive neuroectodermal tumor (PNET) cell line was grown in RPMI 1640 (Invitrogen) with 10% FCS and penicillin/streptomycin/L-glutamine. The UW-228 medulloblastoma cell line was grown in DMEM (Dulbecco's modified Eagle's medium; Invitrogen) with 10% FCS and penicillin/streptomycin/L-glutamine. All cells were grown in a humidified atmosphere at 37° and 5% CO₂. The inhibitors BI2536 (Axon Medchem) and AS 252424 were dissolved in DMSO at 10 mM and diluted into cell culture medium just prior to use.

Western Blotting

Protein expression was analyzed by immunoblotting as previously described (11, 20) using antibodies specific for PI3K p110 γ , LYK5 (STRAD N-13), LKB1, MPP2 (Santa Cruz Biotechnology), AMPK α , phospho-Akt (Ser473; Thr308), ATR, phospho-S6 (Ser 235/236 and Ser 240/244), phospho-4E-BP1 (Cell Signaling Technology) and β -Actin (Sigma). The blots were quantified by densitometry using the software TotalLab Quant (TotalLab Limited).

Apoptosis

For detection of apoptosis, cells were either transfected with siRNA as described above or incubated for 16-24h in the presence or absence of the inhibitors and the Cell Death detection ELISA method (Roche Diagnostics) was used for detection of apoptosis. Alternatively, apoptosis was also measured by propidium iodide staining followed by flow cytometry as previously described (21). Caspase 3/7 activity was measured by using the Caspase-Glo 3/7 Assay (Promega).

Statistical analysis

All tests were performed using GraphPad PRISM 4.03 software. Descriptive statistics including mean and standard error of the mean, one-way ANOVA's and Student's two-tailed *t*-tests were used. *p* values < 0.05 were considered significant.

Results

Identification of protein and lipid kinases involved in medulloblastoma cell proliferation and cisplatin sensitivity

To identify genes essential for medulloblastoma cell proliferation and involved in cellular responses to cisplatin treatment, we designed a robust, cell-based high-throughput kinome-wide RNA interference screen. We systematically inactivated all human protein and lipid kinase genes by RNAi and scored them for inhibition of cell proliferation, in the presence and absence of low dose cisplatin. DAOY medulloblastoma cells were transfected with a 96-well plate arrayed library of siRNA duplexes targeting each of the 719 human kinase genes. We chose the DAOY cell line for the screen, as well as UW-228 and PFSK cell lines for validation experiments, since our previous published work has characterised these cell lines in terms of response to cisplatin and activation of various survival pathways (11, 19, 22-24). The characteristics of the cell lines under study are described in the Supplementary Table S1. We first assessed viability effects induced by siRNAs, in the absence of cisplatin treatment. In the screen, kinases involved in proliferations were defined as kinases whose down-regulation led to a >25% decrease in cell proliferation compared to the scrambled controls, with at least two individual siRNA sequences. In large-scale screens, confirmation of an observed phenotype with redundant silencing reagent offers the most straightforward way of demonstrating RNAi target specificity, allowing exclusion of possible off-target effects (25). Overall, 31 kinases were identified as kinases involved in proliferation (Fig. 1A), with siRNAs targeting MPP2 (membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) and PLK1 (polo-like kinase 1) having the most prominent effect (Fig. 1A). One of the kinases involved in proliferation identified, the proto-oncogene *PIK3CA*, encoding for the PI3K class I_A catalytic subunit p110 α , had been characterized in our previous studies as an important mediator of medulloblastoma cell survival, regulating proliferation, response to polypeptide growth factor stimulation, apoptosis and cell migration (11).

To identify kinases involved in proliferation that further have a role in cellular responses to cisplatin treatment, we performed a secondary sensitized screen in the presence of low doses of cisplatin. The dose of cisplatin chosen for the screen was determined to induce 20% killing in DAOY cells. We first analysed the sensitivity ratios between vehicle- and cisplatin-treated cells. Fig. 1B shows all kinases, that when down-regulated led to a sensitization to cisplatin treatment, with at least two unique siRNA sequences. Cisplatin is a platinum-based chemotherapeutic drug which covalently

binds to purine DNA bases leading to DNA-platinum adducts formation and cellular apoptosis (26). It is one of first and still most commonly used chemotherapeutic drugs, and much is now understood as to how tumors exhibit or acquire resistant to cisplatin treatment (26). Generally, 24 genes were identified as enhancing cell sensitivity to the drug treatment (Fig. 1B); amongst the top hits of our sensitized screen were kinases known to be involved in cellular response to cisplatin treatment, such as the checkpoint kinases ATR, ATM and CHK1, from the double strand DNA repair mechanisms (Fig. 1B). Of the remaining 21 hits, 6 had also shown to have a positive regulatory effect on cell proliferation (Fig. 1A) and were re-examined (Fig. 4A). Z-score analysis revealed a normal distribution of the siRNA hits (Fig. 1C).

***PLK1* silencing or inhibition inhibits medulloblastoma cell proliferation**

The protein kinase PLK1, which was identified in the survival screen (Fig. 1A), plays an essential role during mitosis and maintenance of genomic stability (27). Cancer cells, but not normal cells, have been shown to be susceptible to PLK1 depletion (28), particularly p53-defective cell lines (29). The siRNAs targeting PLK1 were re-assayed in DAOY, PFSK and UW-228 medulloblastoma cell lines (Fig. 2A). Silencing of PLK1 strongly impaired DAOY and PFSK cell proliferation, whereas no effect was observed in UW-228 cells (Fig. 2A). The siRNAs to PLK1 were shown to reduce target mRNA and protein levels by more than 60% (Fig. 2B). Greater than twofold increase in apoptosis was observed upon down-regulation of PLK1 in DAOY cell line (Fig. 2C). Recent studies have demonstrated that the small molecule inhibitor BI2536, a potent and selective inhibitor of PLK1, suppressed growth of a panel of human cancers *in vivo* (30, 31). We then investigated the effects of BI 2536 treatment in medulloblastoma cell proliferation in the cell lines under study. A strong inhibitory effect was observed in the p53-mutant cell line DAOY (IC₅₀ 2.5-5 nM), whereas growth of PFSK and UW-228 cells was only partially reduced (Fig. 2D). These results, in line with the observations upon depletion of PLK1 by siRNA, demonstrate that PLK1 potently controls cell proliferation in medulloblastoma cells, underscoring the role of PLK1 in oncogenic signalling.

***PIK3CG* and *LYK5* silencing inhibits cell proliferation and increases sensitivity to cisplatin treatment**

Two genes identified in the sensitised siRNA screen (Fig. 1) were further validated with two siRNA and one shRNA sequences in three medulloblastoma cell lines, DAOY, PFSK and UW-228 cells: the

phosphoinositide-3-kinase, catalytic, gamma polypeptide (*PIK3CG*; gene ID 5294) and the protein kinase LYK5 (*LYK5*; gene ID 92335) (Fig. 3, Fig. 4A and Fig. S1A). The siRNAs targeting *PIK3CG* and *LYK5* were shown to reduce target mRNA levels by more than 85% (Fig. 3A and Supplementary Fig. S3), which was accompanied by a decrease in protein levels (Fig. 3C). Silencing of *PIK3CG* strongly impaired DAOY and PFSK cell proliferation, whereas a lesser effect was observed in UW-228 cells (Fig. 3B). UW-228 cells displayed low p110 γ expression, possibly explaining the fact that they are less sensitive to *PIK3CG* silencing (Fig. 3B and Fig. 6D). Silencing of *LYK5* also strongly impaired DAOY, PFSK and UW-228 cell proliferation, although some differences were observed between the cell lines (Fig. 3B). Down-regulation of *LYK5* and *PIK3CG* induced apoptosis in the three medulloblastoma cell lines, suggesting that cell death contributes to the effects of the siRNAs on cell survival (Fig. 3D).

Analysis of the phosphorylation status of downstream molecules following silencing of *PIK3CG* revealed an inhibition of basal phosphorylation of the S6 ribosomal protein at the Ser 235/236 and at Ser 240/244 sites, as well as 4E-BP1 phosphorylation (Fig. 3C). Silencing of LYK5 induced a marked decrease in LKB1 protein expression, while the levels of AMPK α were not affected (Fig. 3C). This downregulation of LKB1 expression upon LYK5 silencing was observed in all three medulloblastoma cell lines under study (Fig. 3C and data not shown). Under these experimental conditions, we did not detect any phosphorylation of AMPK α at Thr172 (data not shown). Silencing of *LYK5* also resulted in an inhibition of basal phosphorylation of 4E-BP1 (Fig. 3C). Together these results suggest that *PIK3CG* and *LYK5* are involved in the activation of the mTOR/S6K pathway in medulloblastoma cells.

To confirm the validity of the results from the sensitised siRNA screen, 6 genes that had also been shown to have a positive regulatory effect on cell proliferation (Fig. 1A) were re-examined in proliferation assays in DAOY cells (Fig. 4A) and UW-228 cells (Fig. 4B). Down-regulation of target gene expression was validated by quantitative PCR (TaqMan) in the two medulloblastoma cell lines (Supplementary Fig. S3). These experiments showed that silencing of *ATR*, *LYK5*, *PIK3CG* and *MPP2* enhanced the effects of cisplatin in both cell lines (Fig. 4A and 4B). Further confirmation was provided by establishing dose-response curves upon siRNA mediated silencing of *PIK3CG* (Fig. 4B). siRNA-mediated silencing of *PIK3CG* lowered the EC₅₀ of cisplatin from 1.9 μ M to 0.6 μ M (a 3-fold reduction). shRNA-mediated silencing of *LYK5*, *PIK3CG* and *MPP2* also significantly lowered the EC₅₀ from 5 μ M to 0.5-1 μ M (a 5 to 10-fold reduction), increasing sensitivity to cisplatin treatment (Supplementary Fig. S1B). To test whether this effect is due to an increase in the activity of the apoptotic machinery, we analysed cisplatin-induced apoptosis in cells depleted of *PIK3CG* and *LYK5*

by treating the cells with cisplatin 24h after transfection for an additional 24h. Analysis of PARP cleavage by Western blot revealed a dose-dependent increase in apoptosis upon cisplatin treatment, which was more pronounced in cells where *PIK3CG* was down-regulated (Fig. 4C). Furthermore, relative quantification of histone-complexed cytoplasmatic DNA fragments confirmed that siRNAs for *PIK3CG* and *LYK5* siRNAs sensitised DAOY cells to cisplatin induced apoptosis (data not shown).

Effects of a PI3K p110 γ small molecule inhibitor on medulloblastoma cell proliferation, cell death and pathway activation

The class I_B phosphatidylinositol 3-kinase has been focus of intensive research and is regarded as a promising therapeutic target, particularly in inflammatory diseases (32). Consequently, a number of small molecule inhibitors have been developed and their potential therapeutic applications extensively studied in preclinical models (32). Using a novel PI3K p110 γ small molecule inhibitor, AS252424, we investigated whether the RNAi-mediated effects observed on cell proliferation and response to cisplatin could be reproduced by means of pharmacological targeting of this kinase. After treatment for 72h, AS252424 was shown to decrease the proliferation of 5 medulloblastoma cell lines, including DAOY and PFSK cells in a dose-dependent manner, with IC₅₀ values in the range of 1-15 μ M (Fig. 5A). Cell lines with low p110 γ expression, such as UW-228 and D425, were less sensitive to AS252424 (Fig. 5A and Fig. 6D). However, there was no significant correlation between the IC₅₀ values and the expression of p110 γ in the 6 medulloblastoma cell lines under study (Pearson correlation coefficient $R=-0.5721$, $P=0.2354$). These observations suggest that other factors modulate the sensitivity of medulloblastoma cells to the pharmacological inhibitor of p110 γ . Analysis of the phosphorylation status of downstream molecules following treatment with AS252424 revealed concentration-dependent inhibition of basal phosphorylation of Akt, at the Thr 308 and Ser 437 sites, and S6 ribosomal protein at the Ser 240/244 (Fig. 5B). Furthermore, 24h-treatment with AS252424 enhanced cisplatin-induced apoptosis in medulloblastoma cells (Fig. 5C and data not shown). Our previous studies have shown that treatment with chemotherapeutic agents such as doxorubicin leads to activation of the PI3K/Akt pathway in medulloblastoma cells (11). It has been shown in several human cancer cells that activation of the PI3K/Akt pathway renders cells resistant to commonly used chemotherapeutic agents, including cisplatin and other platinum-based drugs (33, 34). In line with what was observed upon RNAi-mediated down-regulation of p110 γ , AS252424 increased the levels of apoptosis induced by cisplatin treatment, sensitizing cells to cisplatin-induced cell death (Fig. 5C).

Furthermore, treatment of DAOY cells with the p110 γ inhibitor AS 252424 decreased cisplatin-induced phosphorylation of Akt and S6 protein (Fig. 5D). These results unveil a novel role for PI3K p110 γ in human medulloblastoma, as a positive regulator of cell proliferation and underline the importance of PI3K p110 γ in modulating cellular responses upon cisplatin treatment.

Expression of *PIK3CG* and *LYK5* in human medulloblastomas

We next re-analysed expression profiles obtained from DNA microarray analysis in medulloblastoma (17). From the genes identified in the RNAi screen in medulloblastoma (Fig. 1), *PLK1*, *PIK4CA* and *WNK4* showed no significant change in medulloblastoma, compared to normal cerebellum. In contrast, *ATR* and *LYK5* displayed higher expression in medulloblastoma (Figure S2A and S2D), while *MPP2* expression was lower (Figure S2C). We next performed additional experiments to verify that *PIK3CG* and *LYK5* are differentially expressed in human medulloblastoma primary tumors. We initially analyzed mRNA expression by quantitative RT-PCR in a set of representative medulloblastoma surgical specimens. *LYK5* was found to be commonly over-expressed in medulloblastomas (20/23, 87%) whereas up-regulation of *PIK3CG* was restricted to a subset of tumors (9/17, 53%), compared to normal cerebellum (Fig. 6A and B). Protein expression levels were further analyzed by Western blot and expression of PI3K p110 γ was detected in 13/19 of the samples under study (Fig. 6C, 68%). In addition, PI3K p110 γ and *LYK5* expression was detected in 5/7 (71%) of the medulloblastoma cell lines under study (Fig. 6D). In the case of *LYK5* there was no significant correlation between mRNA and protein expression levels in the cell lines (Pearson correlation coefficient $R=0.6587$, $P=0.1548$) (Fig. 6D and Fig. S2F). In the case of p110 γ the mRNA and protein levels did not significantly correlate (Pearson correlation coefficient $R= -0.2183$, $P=0.7817$) (Fig. 6A, 6C, 6D and Fig. S2E).

We next reanalyzed a set of Affymetrix Human Genome U133 Plus 2.0 microarray data comprising expression profiles on a series of 47 medulloblastoma patient samples and 9 normal cerebellum samples. This analysis revealed a significant up-regulation of the gene encoding for *LYK5* in medulloblastomas compared to normal cerebellum (Supplementary Fig. S2A). Interestingly, *LYK5* was found to be expressed at significantly higher levels in medulloblastomas presenting typical 17p breakpoints when compared to the group of medulloblastomas without 17p breakpoints (Supplementary Fig. S2B). The analysis of the tumor samples for *PIK3CG* expression showed variable expression of the gene. A fraction of medulloblastoma tumors also displayed *PIK3CG* over-expression (data not shown).

Discussion

The present report represents one of the first kinome-wide RNAi screens in human brain tumor cell lines and in medulloblastoma. Ideally, such loss-of-function screens should lead to the identification of novel targets for the development of therapeutic strategies for these malignancies, which are associated with a poor outcome in patients (16). Our studies have identified two distinct panels of kinases that contribute to cell proliferation and to the sensitivity of medulloblastoma cells to the commonly used chemotherapeutic agent cisplatin.

As a validation of the survival screen, we performed additional experiments to assess the contribution of PLK1 to medulloblastoma cell proliferation. A pharmacological inhibitor of PLK1 (BI 2536) (31) reduced cell proliferation in DAOY cells, but was less potent in other medulloblastoma cell lines. In addition, siRNA-mediated downregulation of PLK1 had more pronounced effects than the inhibitor in some cell lines, such as PFSK. These contrasting results could potentially be explained by differences in PLK1 expression between the cell lines, and in p53 status, since it was previously shown that PLK1 depletion has more prominent effects in a mutant p53 background (28), which is the case for DAOY. It is also conceivable that there may be a kinase-independent function of PLK1 in cell proliferation in medulloblastoma.

When combining the results of the two RNAi screens, a set of 6 genes comprising *ATR*, *LYK5*, *MPP2*, *PIK3CG*, *PIK4CA* and *WNK4* were identified as contributing to both cell proliferation and resistance to cisplatin treatment in the DAOY medulloblastoma cell line. It is interesting to note here that several protein and lipid kinases were previously identified in comparable sensitised RNAi screens in different human cancer cell lines, including Akt, ATM, ATR, BUB1, phosphatidylinositol 4-kinase and phosphatidylinositol 3-kinase (13, 14). The identities of the PI-kinase isoforms were however different between our study and previous reports (13, 14). A MAGUK family member, namely MPP7 was also identified in an RNAi screen in lung cancer cells investigating paclitaxel resistance (15).

We focused our attention on two genes involved in medulloblastoma proliferation and chemoresistance, namely *LYK5* and *PIK3CG*. This was based on an analysis of the expression of the targets identified in the RNAi screens, which revealed an up-regulation of the expression of these two kinases in subsets of primary medulloblastoma tumor samples and cell lines.

LYK5 is involved in the regulation, assembly and localization of LKB1 and the LKB1-dependent AMPK pathway (35). In medulloblastoma cells, silencing of LYK5 induced a pronounced

down-regulation of LKB1 expression, indicating that LYK5 may be required for LKB1 stability. The AMPK pathway has been studied as a potential target for the development of anti-cancer drugs in various human malignancies (36). Activation of AMPK suppresses the mTOR pathway directly or indirectly via TSC2. The mTOR pathway has been recognized as an important regulator of the sensitivity of human cancer cells to chemotherapeutic agents (13, 37). Indeed, in a previous study, rapamycin exhibited additive cytotoxicity with cisplatin in DAOY cells (10). Although LKB1 is generally thought to function as a tumor suppressor, recent work has also documented its role in the phosphorylation of pro-apoptotic proteins by Akt (38). Together with our data, this may indicate that LYK5/LKB1 may function as a positive regulator of the mTOR/4E-BP1 pathway in medulloblastoma.

The present study represents the first reports on a role for p110 γ as a drug target in brain tumors. Genetic targeting of *PIK3CG* in mice has underlined a central role of this PI3K isoform in inflammation and allergy, as it modulates chemotaxis of leukocytes and degranulation in mast cells (39). In colorectal cancers, *PIK3CG* was initially proposed to function as a tumor suppressor gene (40), a finding disputed by a subsequent study (41). An oncogenic potential was then described for p110 γ , similarly to other class I α PI3K isoforms (42, 43). A recent study described a critical role for p110 γ in pancreatic cancer, and hypothesized that PI3K/p110gamma over-expression is a key event in the disease progression (44).

The availability of isoform-specific p110 γ inhibitors allowed the design of validation experiments to assess the feasibility of targeting this PI3K isoform in medulloblastoma cell lines. Indeed, our results showed for the first time that a pharmacological p110 γ inhibitor impaired the proliferation of medulloblastoma cells and the activation of the mTOR/S6K pathway. The Akt/mTOR/S6K pathway was previously shown to be constitutively activated in primary medulloblastoma and cell lines (11). Our data suggest that p110 γ and LYK5 contribute to this activation, in view of: (i) the over-expression of p110 γ and LYK5 in medulloblastoma; and (ii) the negative impact of targeting these kinases on the basal activation of the pathway in medulloblastoma cell lines.

In addition, the pharmacological p110 γ inhibitor sensitised medulloblastoma cells to cisplatin-induced apoptosis. These effects could be explained by the ability of the p110 γ inhibitor to impair basal and cisplatin-induced activation of Akt in medulloblastoma cells. Therefore, more work is warranted to validate p110 γ as a novel drug target in medulloblastoma. Our previous findings described a role for

the class I_A PI3K p110 α isoform in medulloblastoma proliferation and resistance to doxorubicin (11). However, p110 α was not identified in the sensitised RNAi screen with cisplatin, suggesting that different class I PI3K isoforms may contribute to resistance to cisplatin or doxorubicin. Thus, targeting PI3K signalling may represent an attractive novel approach to develop novel therapies for medulloblastoma. Indeed, there now exist different pharmacological inhibitors of PI3K which have entered clinical trials for adult cancer and could, in the future, be also considered for medulloblastoma (12, 45-47).

Acknowledgements

This work was supported by grants (A. Arcaro) from the Werner und Hedy Berger-Janser-Stiftung zur Erforschung der Krebskrankheiten, the Forschungskredit der Universität Zürich, the Fondation FORCE, the Stiftung zur Krebsbekämpfung and the European Community FP7 (ASSET, project number: 259348). We thank the brain tumour biobank of hospital Necker and the Swiss Pediatric Oncology Group (SPOG) for providing medulloblastoma samples and the translational research department of the Curie Institute for gene expression profiles. We thank A. Schweri-Olac for technical assistance.

References

1. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. *Annu Rev Neurosci* 2001;24:385-428.
2. Gilbertson R. Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. *Eur J Cancer* 2002;38(5):675-85.
3. Freeman CR, Taylor RE, Kortmann RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. *Medical and pediatric oncology* 2002;39(2):99-108.
4. Grill J, Bhangoo R. Recent development in chemotherapy of paediatric brain tumours. *Current opinion in oncology* 2007;19(6):612-5.
5. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. *The lancet oncology* 2004;5(4):209-18.
6. Broderick DK, Di C, Parrett TJ, *et al*. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. *Cancer research* 2004;64(15):5048-50.
7. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. *Development (Cambridge, England)* 2004;131(1):217-28.
8. Hernan R, Fasheh R, Calabrese C, *et al*. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. *Cancer research* 2003;63(1):140-8.
9. Del Valle L, Enam S, Lassak A, *et al*. Insulin-like growth factor I receptor activity in human medulloblastomas. *Clin Cancer Res* 2002;8(6):1822-30.
10. Geoerger B, Kerr K, Tang CB, *et al*. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. *Cancer research* 2001;61(4):1527-32.
11. Guerreiro AS, Fattet S, Fischer B, *et al*. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. *Clin Cancer Res* 2008;14(21):6761-9.
12. Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P, Johnsen JI. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. *Cancer research*;70(1):266-76.

13. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. *Nature cell biology* 2005;7(6):591-600.
14. Swanton C, Marani M, Pardo O, *et al.* Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. *Cancer cell* 2007;11(6):498-512.
15. Whitehurst AW, Bodemann BO, Cardenas J, *et al.* Synthetic lethal screen identification of chemosensitizer loci in cancer cells. *Nature* 2007;446(7137):815-9.
16. Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. *Oncogene* 2009.
17. Fattet S, Haberler C, Legoix P, *et al.* Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. *The Journal of pathology* 2009;218(1):86-94.
18. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. *Methods* 2001;25(4):386-401.
19. von Bueren AO, Shalaby T, Rajtarova J, *et al.* Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. *BMC cancer* 2007;7:19.
20. Arcaro A, Doepfner KT, Boller D, *et al.* Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. *The Biochemical journal* 2007;406(1):57-66.
21. Benzina S, Fischer B, Miterique-Grosse A, *et al.* Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin. *Life sciences* 2006;79(6):513-8.
22. Castelletti D, Fiaschetti G, Di Dato V, *et al.* The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. *Molecular cancer therapeutics*.
23. Shalaby T, von Bueren AO, Hurlimann ML, *et al.* Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. *Molecular cancer therapeutics*;9(1):167-79.
24. von Bueren AO, Shalaby T, Oehler-Janne C, *et al.* RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. *BMC cancer* 2009;9:10.

25. Echeverri CJ, Beachy PA, Baum B, *et al.* Minimizing the risk of reporting false positives in large-scale RNAi screens. *Nature methods* 2006;3(10):777-9.
26. Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer* 2007;7(8):573-84.
27. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. *Nat Rev Cancer* 2006;6(4):321-30.
28. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. *Molecular and cellular biology* 2006;26(6):2093-108.
29. Guan R, Tapang P, Levenson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. *Cancer research* 2005;65(7):2698-704.
30. Lenart P, Petronczki M, Steegmaier M, *et al.* The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. *Curr Biol* 2007;17(4):304-15.
31. Steegmaier M, Hoffmann M, Baum A, *et al.* BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. *Curr Biol* 2007;17(4):316-22.
32. Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? *Nat Rev Drug Discov* 2006;5(11):903-18.
33. Knuefermann C, Lu Y, Liu B, *et al.* HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. *Oncogene* 2003;22(21):3205-12.
34. Yu HG, Ai YW, Yu LL, *et al.* Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. *International journal of cancer* 2008;122(2):433-43.
35. Zehiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. *Science (New York, NY)* 2009;326(5960):1707-11.
36. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: A new therapeutic opportunity in breast cancer. *Critical reviews in oncology/hematology* 2008.
37. Beuvink I, Boulay A, Fumagalli S, *et al.* The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. *Cell* 2005;120(6):747-59.
38. Zhong D, Liu X, Khuri FR, Sun SY, Vertino PM, Zhou W. LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. *Cancer research* 2008;68(18):7270-7.

39. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. *Biochimica et biophysica acta* 2008;1784(1):159-85.
40. Sasaki T, Irie-Sasaki J, Horie Y, *et al.* Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. *Nature* 2000;406(6798):897-902.
41. Barbier M, Attoub S, Calvez R, *et al.* Tumour biology. Weakening link to colorectal cancer? *Nature* 2001;413(6858):796.
42. Denley A, Kang S, Karst U, Vogt PK. Oncogenic signaling of class I PI3K isoforms. *Oncogene* 2007.
43. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proceedings of the National Academy of Sciences of the United States of America* 2006;103(5):1289-94.
44. Edling CE, Selvaggi F, Buus R, *et al.* Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. *Clin Cancer Res*;16(20):4928-37.
45. Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. *Current opinion in cell biology* 2009;21(2):194-8.
46. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. *Oncogene* 2008;27(41):5511-26.
47. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. *Current opinion in pharmacology* 2008;8(4):393-412.

Figure legends

Figure 1. Human kinase siRNA high-throughput screen: kinases involved in proliferation and kinases involved in resistance to cisplatin treatment. A, The figure represents kinases, down-regulation of which led to a >25% decrease in cell proliferation compared to a negative control, with at least two unique siRNA sequences. For each siRNA sequence, averages of 3 independent experiments are shown using a color-coding format. B, 24h following transfection, cells were treated with 0.5 μ M cisplatin for 48hr, before cell proliferation was measured using MTS assay. The figure represents kinases, down-regulation of which led to a sensitization to cisplatin treatment, with at least two unique siRNA sequences. For each siRNA sequence 3 independent experiments were performed, ratio between vehicle- and cisplatin-treated cells were calculated and values >1.5 were considered significant. Sensitivity ratios are shown using a colour-coding format. C, Scatter plot of averaged Z scores from cisplatin sensitivity screen.

Figure 2. Effects of targeting polo-like kinase 1 in medulloblastoma cell lines. A, RNAi-mediated down-regulation of PLK1 decreased proliferation of DAOY (black bars), PFSK (grey bars) and UW-228 (white bars) cells. In DAOY cells strong inhibition of cell proliferation is observed, whereas depletion of PLK1 had no effect in UW-228 cell. B, RT-PCR showing both positive siRNA sequences inducing similar levels of downregulation of PLK1 mRNA 48h following transfection (top panel). Western blot analysis confirming PLK1 down-regulation by the siRNA in the 3 cell lines (mid panel). TaqMan-based qRT-PCR confirmed downregulation of PLK1 mRNA in the 3 cell lines. DAOY (black bars), PFSK (grey bars) and UW-228 (white bars) (bottom panel). C, Down-regulation of PLK1 induces apoptosis in DAOY cells. D, PLK1 small molecule pharmacological inhibitor, BI 2536, strongly impaired DAOY cell proliferation, whereas growth of PFSK and UW-228 was only partly inhibited (DAOY: black bars; PFSK: grey bars; UW-228: white bars). * $P < 0.05$, compared with control.

Figure 3. *PIK3CG* and *LYK5*: roles in proliferation, apoptosis and chemoresistance. A, RNAi-mediated down-regulation of *PIK3CG* and *LYK5* mRNA expression in DAOY cells. B, RNAi-mediated down-regulation of *PIK3CG* and *LYK5* decreased proliferation of DAOY (black bars), PFSK (grey bars) and UW-228 (white bars) cells. C, In DAOY cells, RNAi-mediated targeting of *PIK3CG* led to downregulation of PI3K p110 γ protein expression and inhibited phosphorylation of S6 and 4E-BP1

downstream signalling proteins. RNAi-mediated targeting of *LYK5* led to downregulation of *LYK5* protein expression, *LKB1* downregulation and inhibited phosphorylation of *4EBP1* protein. D, RNAi-mediated down-regulation of *PIK3CG* and *LYK5* increased apoptosis in DAOY (black bars), PFSK (grey bars) and UW-228 (white bars) cells. * $P < 0.05$, compared with control.

Figure 4. Kinases involved in cell proliferation and chemoresistance. A, The graph shows siRNA-mediated effects in DAOY cell proliferation in the presence (0.5 μ M; white bars) and absence (grey bars) of cisplatin for those kinases that scored positive in both screens. B, The graph shows siRNA-mediated effects on UW-228 cell proliferation in the presence of cisplatin (2.0 μ M) for those kinases that scored positive in both screens. The ratio of cell proliferation of cells treated with cisplatin to vehicle-treated cells is presented. C, RNAi-mediated targeting of *PIK3CG* led to sensitization of DAOY cells to cisplatin treatment (siRNA control: black circles; siRNA *PIK3CG*: white circles). D, RNAi-mediated targeting of *PIK3CG* enhanced cisplatin-induced apoptosis, as measured by Western blot analysis of PARP cleavage. * $P < 0.05$, cisplatin-treated sample compared with control.

Figure 5. Effects of treatment with a novel small kinase inhibitor of PI3K p110 γ on medulloblastoma cells. A-C, Pharmacological inhibition of the PI3K p110 γ isoform, the protein encoded by *PIK3CG*, led to inhibition of cell proliferation (black diamonds: DAOY; black squares: PFSK; black triangles: UW-228; white squares: D341; black circles: D458; white circles D425) (A), inhibition of basal phosphorylation of Akt in DAOY cells (B), increased cisplatin-induced apoptosis (black bars: 0 μ M AS252424; grey bars: 1 μ M AS252424) in PFSK cells (C) and impaired cisplatin-induced phosphorylation of Akt in DAOY cells (D).

Figure 6. Relative expression levels of the kinases *LYK5* and p110 γ in primary medulloblastoma tumor samples. A-B, Gene expression ratios (log scale) measured in tumors by TaqMan-based qRT-PCR. The relative gene expression level is presented as fold change of tumor versus normal cerebellum. Error bars are too small to be seen. Samples from series 1 were from the Necker Hospital Tumor (17). Samples from series 2 were from the SPOG (Table S2). C, Protein expression of p110 γ was analyzed in an additional, independent set of medulloblastoma tumor surgical specimens (N=19, Table S2). D, Protein expression of *LYK5* and p110 γ was analyzed in human medulloblastoma cell lines (N=7).

Whole cell lysate was extracted and total protein was analyzed for p110 γ and β -Actin by Western Blot. Tumors and cells lines commonly over-express LYK5 and p110 γ . In Figure 6A Samples 14-17 correspond to the tumor samples nr. 4, 12, 15 and 18 in Figure 6C. Samples 14-23 in Figure 6B correspond to the tumor samples nr. 4-9, 11, 12, 15 and 18 in Figure 6C.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

